The new law imposes restrictions and regulations on pharmacy benefit managers, or PBMs, that negotiate prescription drug prices between manufacturers, health insurance companies and pharmacies.

As the rising cost of prescription medications in the United States becomes an increasing barrier for millions of people, how ...

Giving small-molecule drugs the same 13-year exemption from price negotiation as biologics would cost the federal government billions of dollars, argue three Harvard researchers ...

Federal agencies have scheduled a series of three web-based "listening sessions" to hear from commenters about issues that might be limiting competition in the U.S. prescription drug market and ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

UroGen Pharma's FDA nod for UGN-102 fuels recovery, but cash burn raises financing risks. Check out why I am maintaining my ...

More than 40 reports identify hospital rates and prescription drug prices as the main drivers of rising healthcare costs. But ...

Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...

Shopify to pilot USDC payments with Coinbase and Stripe, enabling U.S. merchants to accept stablecoins and expanding to ...

Independent Sens. Bernie Sanders of Vermont and Angus King of Maine have introduced a bill that would ban pharmaceutical ...

A change to Medicare payments, set to take effect in 2028, could force infusion centers to close, leaving patients in the lurch.

Prosper Stars & Stripes, a long/short equity fund, recently released its first quarter 2025 investor letter. A copy of the ...